• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

RUCAPARIB Drug Record

  • Summary
  • Interactions
  • Claims
  • RUCAPARIB chembl:CHEMBL1173055 ApprovedAntineoplastic

    Alternate Names:

    AG-014699
    RUCAPARIB
    AG-14447
    AG014699
    PF-01367338
    AG14447
    RUBRACA
    chemidplus:283173-50-2
    pubchem.compound:9931954
    drugbank:12332
    chembl:CHEMBL1173055
    rxcui:1862579

    Drug Info:

    FDA Approval Ovarian cancer (with BRCA mutation)
    Drug Class Small molecule inhibitor
    (9 More Sources)

    Publications:

    Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.
    Drew et al., 2016, Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer., Br. J. Cancer
    Shroff RT et al., 2018, Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> Mutation., JCO Precis Oncol
    Swisher et al., 2017, Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial., Lancet Oncol.
    Wang et al., 2016, RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance., J. Clin. Invest.
    Kondrashova O et al., 2017 Sep, Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma., Cancer Discov
    Sulkowski et al., 2017, 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity., Sci Transl Med
    Chatterjee et al., 2013, PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells., PLoS ONE
    Solomon et al., 2011, Mutational inactivation of STAG2 causes aneuploidy in human cancer., Science
    Bailey et al., 2014, Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition., Mol. Cancer Ther.
  • RUCAPARIB   PARP2

    Interaction Score: 1.07

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction PARP 1, 2 and 3 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions PharmGKB

  • RUCAPARIB   SLC47A2

    Interaction Score: 0.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RUCAPARIB   SLC47A1

    Interaction Score: 0.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RUCAPARIB   PARP1

    Interaction Score: 0.78

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Mechanism of Interaction PARP 1, 2 and 3 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions PharmGKB

  • RUCAPARIB   PARP3

    Interaction Score: 0.75

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction PARP 1, 2 and 3 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions PharmGKB

  • RUCAPARIB   STAG2

    Interaction Score: 0.7

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    21852505 24356817


    Sources:
    JAX-CKB

  • RUCAPARIB   BRCA2

    Interaction Score: 0.67

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type ovarian cancer
    Response Type predicted – sensitive
    Approval Status FDA approved

    PMIDs:
    26779812 27002934 30051098 27908594


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC PharmGKB OncoKB

  • RUCAPARIB   PALB2

    Interaction Score: 0.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    CIViC

  • RUCAPARIB   ATR

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • RUCAPARIB   SLC22A6

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RUCAPARIB   BRCA1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type ovarian carcinoma
    Response Type sensitive
    Approval Status Clinical Study

    PMIDs:
    27454289 27002934 26779812 28588062 27908594


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC PharmGKB OncoKB

  • RUCAPARIB   SLC22A8

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RUCAPARIB   SLCO1B3

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RUCAPARIB   DYRK1A

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RUCAPARIB   CYP2C8

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RUCAPARIB   ABCC4

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RUCAPARIB   PIM1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RUCAPARIB   PRKD2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RUCAPARIB   UGT1A1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RUCAPARIB   CDK1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RUCAPARIB   PTEN

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AZD6482 + Rucaparib
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive

    PMIDs:
    23565244


    Sources:
    JAX-CKB

  • RUCAPARIB   SLCO1B1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RUCAPARIB   MET

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    combination therapy Foretinib + Rucaparib
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    26779812


    Sources:
    JAX-CKB

  • RUCAPARIB   ATM

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • RUCAPARIB   ABCG2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RUCAPARIB   IDH1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type sensitive

    PMIDs:
    28148839


    Sources:
    JAX-CKB

  • RUCAPARIB   YES1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RUCAPARIB   ABCB1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RUCAPARIB   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • RUCAPARIB   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • RUCAPARIB   CYP2C9

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RUCAPARIB   CYP2C19

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RUCAPARIB   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • MyCancerGenome: RUCAPARIB

    • Version: 20-Jun-2017

    Alternate Names:
    RUCAPARIB Generic Name
    RUBRACA Trade Name

    Drug Info:
    Drug Class Small molecule inhibitor
    FDA Approval Ovarian cancer (with BRCA mutation)

    Publications:

  • JAX-CKB: Rucaparib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Kondrashova O et al., 2017 Sep, Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma., Cancer Discov
    Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.
    Drew et al., 2016, Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer., Br. J. Cancer

  • CIViC: RUCAPARIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Swisher et al., 2017, Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial., Lancet Oncol.
    Shroff RT et al., 2018, Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> Mutation., JCO Precis Oncol

  • TALC: RUCAPARIB

    • Version: 12-May-2016

    Alternate Names:
    RUCAPARIB Primary Drug Name
    RUCAPARIB Drug Generic Name

    Drug Info:

    Publications:

  • DTC: RUCAPARIB

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1173055 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Rucaparib

    • Version: 2020.06.01

    Alternate Names:
    D01SHZ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1173055

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: RUCAPARIB

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: RUCAPARIB

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: rucaparib

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: Rucaparib

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1173055

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Rucaparib

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21